DRUG AND DEVICE COST-EFFECTIVENESS STUDY PROTOCOLS
DRUG AND DEVICE COST-EFFECTIVENESS STUDY PROTOCOLS could be designed by FDA, the agency's Office of Device Evaluation Director Susan Alpert said Nov. 15 at a Blue Cross/Blue Shield conference on technology assessment in Arlington, Va. Noting that it has been "rumored that there might be a role for either FDA or another agency within [the Public Health Service] to look at cost effectiveness," Alpert said, "we would see a role for ourselves in designing" cost-effectiveness protocols "because clinical protocols and the evaluations of the products...are in fact within our purview."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth